Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2423501 | 0.83 | TSHR (0.46) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL31081959 | 0.79 | TSHR (0.39) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL27895311 | 0.76 | DYRK1A (0.47) | DYRK1AALDH1A1KDM4EMEN1GAA | |
| SCHEMBL1161369 | 0.76 | CYP3A4 (0.50) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL31172444 | 0.76 | CYP3A4 (0.50) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL101977 | 0.76 | DYRK1A (0.47) | DYRK1AALDH1A1KDM4EMEN1GAA | |
| SCHEMBL29517818 | 0.75 | — | — | |
| Water SCHEMBL27523013 | 0.75 | TSHR (0.50) | DYRK1AALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL73332 | 0.75 | — | — | |
| SCHEMBL30539289 | 0.74 | KDM4E (0.53) | DYRK1AALDH1A1KDM4EMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | claimed |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | BANKSTON DONALD | 2010-05-20 | — | — | US | claimed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | claimed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1542992-A2 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | Bayer Corporation (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004029045-A2 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | claimed |
| EP-1370553-A2 | RHO-KINASE INHIBITORS | Bayer Corporation (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030220357-A1 | Process for preparing quinazoline Rho-kinase inhibitiors and intermediates thereof | BAYER HEALTHCARE LLC | 2003-11-27 | — | — | US | claimed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | claimed |
| WO-2002076976-A2 | RHO-KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-03 | — | — | WO | claimed |
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250171447-A1 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-05-29 | — | — | US | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| WO-2025056017-A1 | FUSED BICYCLIC HETEROARYLS AS PARG INHIBITORS AND USES THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2025-03-20 | — | — | WO | disclosed |
| CN-1205693-A | Quinoline and quinazoline compounds useful in therapy | PFIZER RES & DEV (IE) | 1999-01-20 | — | — | CN | disclosed |
| EP-0090972-B1 | INDAZOLE DERIVATIVES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1990-05-30 | — | — | EP | disclosed |
| US-4751302-A | ANTIINFLAMMATORY, ANTIULCER AGENTS, ANALGESICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1988-06-14 | — | — | US | disclosed |
| US-4533731-A | ANTIINFLAMMATORY AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-08-06 | — | — | US | disclosed |
| EP-0090972-A2 | Indazole derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142313-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | DYRK1A 698/4885ALDH1A1 3561/4885KDM4E 1157/4885 |
| US-20250171447-A1 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | ADORA2A, ADORA2B, ADORA1 | DYRK1A 607/4885ALDH1A1 483/4885KDM4E 3489/4885 |
| US-20030220357-A1 | Process for preparing quinazoline Rho-kinase inhibitiors and intermediates thereof | ROCK1, ROCK2, RHOT2 | DYRK1A 644/4885ALDH1A1 3717/4885KDM4E 1158/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | DYRK1A 4410/4885ALDH1A1 621/4885KDM4E 1198/4885 |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | CIT, PDE3A, PDE2A | DYRK1A 172/4885ALDH1A1 3152/4885KDM4E 960/4885 |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | DYRK1A 698/4885ALDH1A1 3561/4885KDM4E 1157/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | DYRK1A 3707/4885ALDH1A1 4172/4885KDM4E 4059/4885 |
| US-20100125139-A1 | PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF | ROCK1, ROCK2, CIT | DYRK1A 567/4885ALDH1A1 4305/4885KDM4E 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.